Product logins

Find logins to all Clarivate products below.


Keval Vasavada

Director, Consulting

Keval Vasavada comes with a right mix of consulting as well as industry experience in pharmaceutical and life sciences.

He holds over 13 years of experience spanning corporate strategy, operations, new process set-up, new product launches, corporate finance, fund raising and commercial deals. Prior to Clarivate, Keval worked with Cipla Pharmaceuticals and IQVIA Consulting.

He has worked on developing disruptive, competitive and sustainable business model for biosimilar business in his previous assignment. He understands the nuances of biopharma manufacturing and has spearheaded commercial discussions with top suppliers of biopharma equipment in the past.

During his consulting stint, he has led projects involving asset portfolio strategy, market entry strategy, commercial due diligence, opportunity assessment for novel therapies in Japan, Asia-Pacific, US, and Europe. He has a rich exposure of working across a breadth of therapeutic areas involving oncology, immunology, neurology, respiratory, rare diseases, and metabolic disorders.

Keval has completed his MBA from the prestigious Indian Institute of Management, Lucknow (India) and did his B.Tech. in Dairy Technology from Dairy Science College, Anand (Gujarat, India).

Related resources

支付方愿意为便利性买单的市场准入“最佳切入点” 支付方愿意为便利性买单的市场准入“最佳切入点”
Blog June 3, 2026
支付方愿意为便利性买单的市场准入“最佳切入点”
医疗保险 定价 市场准入 真实世界数据 美国市场 药政法规
2026 年值得关注的 5 大医疗技术趋势 2026 年值得关注的 5 大医疗技术趋势
Blog May 28, 2026
2026 年值得关注的 5 大医疗技术趋势
AI/机器学习 GLP-1 医疗技术 带量采购(VBP) 日间手术中心(ASC)
《2026年最值得关注的药物》问答:礼来的下一代减肥药 《2026年最值得关注的药物》问答:礼来的下一代减肥药
Blog March 26, 2026
《2026年最值得关注的药物》问答:礼来的下一代减肥药
GLP-1 最值得关注的药物
为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇 为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇
Blog March 2, 2026
为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇
AI/机器学习 GLP-1 临床试验 交易 药政法规 衰老生物学